Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- ID
- NCT05682170
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 95 study participants
- Last Updated